Search Within

Helen Hyeong-Eun Won

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (25)
  2. Meeting Abstract (9)
  3. Research Letter (1)
Groups
  1. GSK Faculty (35)
  2. Human Oncology and Pathogenesis Program (35)
  3. Sloan Kettering Institute Postdocs (35)
  4. Department of Pathology and Laboratory Medicine (34)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (33)
  6. Department of Medicine (32)

More Groups

People
  1. Michael Berger (31)
  2. David Solit (15)
  3. Maurizio Scaltriti (15)
  4. David Hyman (13)
  5. Alison Schram (10)
  6. Barry Taylor (9)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (6)
  4. 2020 (3)
  5. 2019 (5)
  6. 2018 (3)

More Years

Publications
  1. Cancer Research (6)
  2. Cancer Discovery (4)
  3. Blood (3)
  4. Nature (3)
  5. Nature Communications (3)
  6. Nature Medicine (3)

More Publications

Publishers
  1. American Association for Cancer Research (11)
  2. Nature Publishing Group (11)
  3. American Society of Hematology (3)
  4. Cell Press (2)
  5. Oxford University Press (2)
  6. American Association for the Advancement of Science (1)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Loss of PTEN leads to clinical resistance to the PI3K alpha inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure
    Meeting Abstract

    Castel, P.; Juric, D.; Won, H.; Ainscough, B.; Ellis, H.; Ebbesen, S.; Griffith, M.; Griffith, O.; Iyer, G.; Sgroi, D.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Vemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Kim, E.; Saven, A.; Wadleigh, M.; Stone, R. M.; Barrientos, J. C.; Rai, K. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: A case of convergent evolution under selective therapeutic pressure
    Meeting Abstract

    Castel, P.; Juric, D.; Griffith, M.; Griffith, O. L.; Won, H. H.; Ainscough, B.; Ellis, H.; Ebbesen, S.; Gopakumar, I.; Quadt, C.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
    Journal Article

    Nissan, M. H.; Pratilas, C. A.; Jones, A. M.; Ramirez, R.; Won, H.; Liu, C.; Tiwari, S.; Kong, L.; Hanrahan, A. J.; Yao, Z.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    Journal Article

    Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T. A.; more...
    Nature Genetics (2013)

    Fulltext@MSK | Save